Maxim Group analyst Jason McCarthy reiterated a Buy rating and $5 price target on Adial Pharmaceuticals Inc (NASDAQ: ADIL) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Momentum Movers Trader Talk

Adial Pharmaceuticals (ADIL) Halted on LUDPDecember 13, 2018 10:55 AM Adial Pharmaceuticals (ADIL) Surges on Plans to Expand Lead Asset AD04 into Opioid AddictionDecember 13, 2018 9:27 AM Pre-Open Movers 12/13: (GE) (NBEV) (CIEN) Higher; (AGTC) (TLRD) (LLNW) Lower (more...)December 13, 2018 9:26 AM Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as FentanylDecember 13, 2018 8:00 AM